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Introduction
•   Edoxaban, a direct FXa inhibitor, is approved for the treatment and 
secondary prevention of acute VTE, based on its comparable efficacy and 
superior safety versus warfarin during the 12 month Hokusai-VTE trial1
•   The ETNA-VTE-Europe (NCT02943993) study is being conducted to 
gain further insight into the efficacy and safety of extended treatment with 
edoxaban up to 18 months in routine clinical practice2
•   There are data to suggest that the index clinical manifestation of 
venous thromboembolism (VTE; either deep vein thrombosis [DVT] or 
pulmonary embolism [PE] with or without DVT) strongly predicts the 
type of recurrence. However, data on the association between index 
manifestation and absolute recurrent VTE rates are conflicting3
•   This poster assesses the patient characteristics and evaluates the rates 
and associations between the index VTE event (PE with or without DVT 
versus DVT alone) and 12-month outcomes
Methods
•   ETNA-VTE-Europe is an 18-month, prospective, single-arm,  
non-interventional, multinational, post-authorisation safety study2
•   A total of 2407 patients with acute symptomatic VTE who were 
receiving edoxaban in routine practice were enrolled from eight 
European Countries (Austria, Belgium, Germany, Ireland, Italy, the 
Netherlands, Switzerland and the United Kingdom)
•   At 12 months, patients with an index event of PE with or without DVT 
(PE±DVT) were compared with those with an index event of DVT without PE
Results
•   Patients with acute PE±DVT had a slightly higher age, a higher 
percentage of frailty, more hypertension and a more frequent history 
of PE than patients with DVT only (Table 1)
•   Patients with DVT alone had more history of chronic venous 
insufficiency and an increased history of prior DVT (Table 1)
•   Overall, VTE recurrence was 2.83%, rates of any bleeding 13.00%, 
any stroke 0.83%, major bleeding 1.91% and all-cause mortality 
3.37% (Figure 1–3)
•   Patients with index PE±DVT had numerically higher rates of all-cause 
mortality (4.08% versus 2.85%), cardiovascular mortality (1.69% 
versus 1.21%) and major bleeding (2.39% versus 1.57%) rates than 
those with index DVT alone (Figure 2 and 3)
Conclusions
•   Low rates of bleeding and venous thromboembolism events were 
reported after 12 months of treatment with edoxaban in clinical 
practice reinforcing the safety and effectiveness of edoxaban 
treatment in VTE patients
•   Patients with index pulmonary embolism with or without deep 
vein thrombosis reported a higher mortality and bleeding events 
than those with deep vein thrombosis alone
•  The 18-month outcomes results are awaited
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Table 1. Patient baseline characteristics by type of index event 
Patient characteristics Overall  [N=2407]
PE±DVT
[N=1004] 
DVT alone
[N=1403] 
Female, n (%) 1121 (46.6) 485 (48.3) 636 (45.3)
Age, years, mean ± SD 63.2 ± 15.87 64.4 ± 15.29 62.3 ± 16.23
Recalc. eGFR (Cockroft-Gault, mL/min), 
mean ± SD 94.2 ± 38.97 92.8 ± 38.30 95.3 ± 39.47
Frailty (physician judgement), n (%) 306 (12.7) 140 (14.0) 166 (11.8)
Medical history, n (%)
   Hypertension
   Chronic venous insufficiency
   COPD
   Cancer
      Cancer still active*
   Bleeding history
   History of major or CRNM bleeding
   History of major bleeding
   Ischaemic stroke
1041 (43.2)
  264 (11.0)
  162 (6.7)
234 (9.7)
    89 (38.2)
  71 (2.9)
  46 (1.9)
  22 (0.9)
  58 (2.4)
476 (47.4)
75 (7.5)
86 (8.6)
110 (11.0)
  38 (34.9)
47 (4.7)
28 (2.8)
12 (1.2)
37 (3.7)
565 (40.3)  
189 (13.5)
    76 (5.4)
124 (8.8)
    51 (41.1)
  24 (1.7)
  18 (1.3)
  10 (0.7)
  21 (1.5)
Prior VTE, n (%)
   Prior PE±DVT
   Prior DVT only
177 (7.4)
  388 (16.1)
112 (11.2)
110 (11.0)
65 (4.6)
278 (19.8)
Edoxaban treatment at baseline, n (%)
   Edoxaban 60 mg
   Edoxaban 30 mg
2100 (87.2)
  307 (12.8)
891 (88.7)
113 (11.3)
1209 (86.2)
  194 (13.8)
*Percentage based on patients with cancer history
COPD, chronic obstructive pulmonary disease; CRNM, clinically relevant non-major; DVT, deep vein thrombosis; 
eGFR, estimated glomerular filtration rate;  
PE, pulmonary embolism; SD, standard deviation; VTE, venous thromboembolism
DVT, deep vein thrombosis; PE, pulmonary embolism; VTE, venous thromboembolism CV, cardiovascular; DVT, deep vein thrombosis; PE, pulmonary embolism
CRNM, clinically relevant non-major; DVT, deep vein thrombosis; GI, gastrointestinal; ICH, intracranial 
haemorrhage; ISTH, International Society on Thrombosis and Haemostasis; PE, pulmonary embolism
Figure 1. Events of venous thromboembolism and stroke during 12-month follow-up Figure 3. Deaths reported during 12-month follow-up
Figure 2. Bleeding events during 12-month follow-up
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